How Brepocitinib (Lisraya) Works in Dermatomyositis: Mechanism Explained

In August 2026, the FDA approved the first oral drug built specifically for dermatomyositis — brepocitinib, sold as Lisraya. For decades, this rare autoimmune disease was treated with therapies borrowed from other conditions. This video breaks down the interferon biology driving dermatomyositis, how brepocitinib works, the JAK-STAT signaling pathway it targets, and the phase 3 VALOR trial data behind its approval. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. https://www.fda.gov/news-events/press... 2. https://www.the-rheumatologist.org/ar... 3. Qudsiya, Z., & Waseem, M. (2023). Dermatomyositis. In StatPearls. StatPearls Publishing. 4. https://www.mda.org/disease/dermatomy... 5. Paik, J. J., Vencovský, J., Charles-Schoeman, C., Wright, G. C., Vleugels, R. A., Goriounova, A. S., Mudd, P. N., Jr, & Aggarwal, R. (2025). Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clinical and experimental rheumatology, 43(2), 354–363. https://doi.org/10.55563/clinexprheum... 6. Liu, X., Feng, Z., Che, C., Xin, G., Li, L., & Xu, X. (2026). An Overview of Small-Molecule Agents for the Treatment of Dermatomyositis. Current Topics in Medicinal Chemistry. 7. Vleugels, R. A., Paik, J. J., Bauer Ventura, I., Mangold, A. R., Gandiga, P. C., Haemel, A., Chinoy, H., Hussain, Y. M., Sivakumar, K., Griger, Z., Lee, E. B., Bozan, F., Hsu, C. Y., Femia, A., Dimachkie, M. M., Min, M. S., Mozaffar, T., Charles-Schoeman, C., Fernandez, D. R., Onajin, O., … VALOR Investigators (2026). A Phase 3 Trial of Brepocitinib in Dermatomyositis. The New England journal of medicine, 394(19), 1883–1893. https://doi.org/10.1056/NEJMoa2503531 #Dermatomyositis #Brepocitinib #JAKInhibitor #Lisraya #Autoimmune #Rheumatology #Immunology #RareDisease #MedicalEducation #TYK2 #InterferonSignaling #FDAApproval #MedEd #Pharmacology